Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Illumina    ILMN

ILLUMINA (ILMN)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 09/20 10:00:02 pm
356.32 USD   +1.70%
09/14ILLUMINA : Report
CO
09/11ILLUMINA : Report
CO
09/06ILLUMINA : Report
CO
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Illumina : Files New Patent Infringement Suit Against Premaitha Health plc

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/07/2017 | 03:04pm CEST

Illumina, Inc. (NASDAQ:ILMN) announced today that the company has filed a new patent infringement suit against Premaitha Health plc in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. Illumina is seeking all available remedies, including damages and injunctive relief.

The new suit accuses Premaitha’s IONA® Test of infringing European Patent (UK) 1 524 321 B2 titled, “Non-invasive Detection of Fetal Genetic Traits,” which is exclusively licensed to Illumina from Sequenom, Inc.

Illumina and its wholly owned subsidiary, Verinata Health, Inc., previously filed suits in the UK against Premaitha accusing its Iona test of infringing European Patent (UK) 0 994 963 B2, European Patent (UK) 1 981 995 B1, European Patent (UK) 2 183 693 B1, European Patent (UK) 2 385 143 B1 and European Patent (UK) 2 514 842 B1. Those suits remain pending.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ILLUMINA
09/19ILLUMINA : Service Agreement for Scientific Equipment
AQ
09/14ILLUMINA : Report
CO
09/11ILLUMINA : Report
CO
09/06ILLUMINA : Receives Approval of MiSeq™Dx System in China
AQ
09/06ILLUMINA : Report
CO
09/05INSCRIPTA : Announces Strategic Acquisition of Solana Biosciences
PR
09/05ILLUMINA : NovaSequ 6000 S1 reagent kit and the free adapter Blocking Reagent ki..
AQ
08/30ILLUMINA : to Webcast Upcoming Investor Conference Presentation
BU
08/27ILLUMINA : Receives Approval of MiSeq™Dx System in China
BU
08/27ILLUMIN : Illumina
AQ
More news
News from SeekingAlpha
09/14Canaccord bullish on medical diagnostic firms 
09/13Pacific Biosciences Inching Closer To A Key Event 
09/10Invesco S&P 500 Equal Weight ETF (RSP) August Summary 
09/07Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update 
09/06Guardant Health on deck for IPO 
Financials ($)
Sales 2018 3 310 M
EBIT 2018 915 M
Net income 2018 754 M
Finance 2018 1 439 M
Yield 2018 -
P/E ratio 2018 68,79
P/E ratio 2019 63,57
EV / Sales 2018 15,4x
EV / Sales 2019 13,4x
Capitalization 52 379 M
Chart ILLUMINA
Duration : Period :
Illumina Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ILLUMINA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 343 $
Spread / Average Target -3,7%
EPS Revisions
Managers
NameTitle
Francis A. deSouza President, Chief Executive Officer & Director
Jay T. Flatley Executive Chairman
Ostadan Omead Executive Vice President-Products & Operations
Sam A. Samad Chief Financial Officer & Senior Vice President
Mostafa Ronaghi Chief Technology Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ILLUMINA60.36%52 379
THERMO FISHER SCIENTIFIC26.95%97 678
DANAHER CORPORATION16.32%75 553
INTUITIVE SURGICAL53.77%63 833
BOSTON SCIENTIFIC CORPORATION52.56%52 302
ROYAL PHILIPS24.60%43 570